Description
Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia.
In the United States, gemtuzumab ozogamicin is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for adults and children one month and older and for the treatment of relapsed or refractory CD33-positive AML in adults and children two years and older.
Contact Sourcing Facilitation Team
Contact Name: Mr. Tarun Garg
Address: 60/4, Yusaf Sarai, Near Indian Oil Corp., New Delhi – 110 016 (India)
Mobile/WhatsApp. 9891296838.
Email: support@southdelhipharma.com, southdelhipharma@gmail.com
Get Access MYLOTARG (gemtuzumab ozogamicin) In India on request.
MYLOTARG may be imported for personal treatment under the Named Patient Program (NPP) across India, including Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Aurangabad, Pune, Bengaluru, Hyderabad, Chennai, Visakhapatnam, Coimbatore, and other regions of India.
Note: South Delhi Pharma, act as a facilitation partner and do not manufacture, sell, or distribute pharmaceutical products. All facilitation activities are conducted in accordance with applicable Indian pharmaceutical and trade regulations.
